These data indicated that human Vγ9Vδ2 T cells could kill MDA-MB-231 cells and restrain tumor growth, and the IDO enzyme inhibitor themselves could not kill breast cancer cells efficiently, but could enhance the antitumor efficacy of Vγ9Vδ2 T cells. Here, IDO1 is linked to breast carcinoma.